The market is pricing the stock in line with historical averages, assuming steady-state growth.
Fragile underlying quality score of 43/100; weak margins or elevated debt leverage warrant caution.
Wall Street forecasts a balanced outlook with consensus price targets near the current price.
Verdict: Average quality business weighed down by significant growth concerns.
Wall Street sentiment is generally neutral alongside robust expected earnings growth. This outlook is strongly supported by highly attractive capital returns, anchored by a strong dividend yield, though free cash flow coverage appears tight.
MPX demonstrates adequate business quality with stable profitability. This is backed by a fortress balance sheet, holding significant net cash ($44M) and minimal debt risk.
The company is facing top-line contraction (-13.8% 3Y CAGR) however, earnings have severely contracted over the same period. However, profitability remains a major concern with severely compressed operating margins (4.9%).
| Financial Metric | Trend (12Q) | Latest Qtr | 1Y Growth | 3Y CAGR | 5Y CAGR | 10Y CAGR |
|---|---|---|---|---|---|---|
| Revenue | $66.5M | +3.3% | -13.8% | +0.4% | +1.7% | |
| EBITDA | $3.0M | — | -31.6% | — | — | |
| Net Income | -$2.1M | -36.2% | -34.4% | — | -2.3% | |
| EPS (Diluted) | $-0.06 | -34.0% | -34.6% | -10.0% | -1.7% | |
| Free Cash Flow | $8.6M | -40.1% | -31.7% | -11.7% | — |
| Metric | TTM | 3Y Avg | 5Y Avg | 10Y Avg |
|---|---|---|---|---|
| Gross Margin | 18.6% | 20.6% | 21.9% | 21.9% |
| Operating Margin | 4.9% | 8.8% | 10.4% | 10.6% |
| Net Margin | 2.8% | 7.7% | 8.7% | 8.5% |
| FCF Margin | 5.1% | 9.6% | 8.2% | 8.6% |
| Quarter | EPS Est. | EPS Act. | Surprise | EPS | Rev |
|---|---|---|---|---|---|
| Q2'26Latest | — | $0.05 | — | ||
| Q1'26 | $0.10 | $0.10 | +0.0% | ||
| Q4'25 | $0.10 | $0.07 | -30.0% | ||
| Q3'25 | $0.12 | $0.12 | +0.0% | ||
| Q2'25 | $0.08 | $0.06 | -25.0% | ||
| Q1'25 | $0.05 | $0.12 | +140.0% | ||
| Q4'24 | $0.08 | $0.10 | +25.0% | ||
| Q3'24 | $0.14 | $0.14 | +0.0% |
Total return is +6.3% (1Y), lagging the benchmark by -18.7%
| Period | Total Return | vs S&P 500 (Alpha) | Dividend Contribution |
|---|---|---|---|
| YTD | -3.5% | -12.8% | — |
| 1Y | +6.3% | -18.7% | +6.8% |
| 3YCAGR | -13.4% | -32.9% | +14.7% |
| 5YCAGR | -8.7% | -20.4% | +18.6% |
| 10YCAGR | +4.8% | -8.7% | — |
The S&P 500 is at 31.3x trailing P/E — Expensive relative to historical averages.
Quick answers to common questions about Marine Products Corporation (MPX) valuation, health, and returns.
Based on peer relative multiples, Marine Products Corporation appears Fair versus peers compared to industry peers.
Marine Products Corporation has multiple valuation anchors: Peer Relative Fair Value: $8.12. A convergence of these signals offers higher conviction.
Marine Products Corporation displays fair financial health with a composite quality score of 43/100, supported by a Altman Z-Score of 11.4 (safe zone), Piotroski F-Score of 4/9, Return on Invested Capital (ROIC) of 13.3%.
Marine Products Corporation pays a 6.9% dividend yield, covered by a 172% payout ratio with 1 years of growth, supplemented by a 0.4% buyback yield.
Marine Products Corporation's current growth trajectory is Accelerating. The company achieved +3.3% 1Y revenue growth and -34.0% 1Y EPS growth, compared to its 3Y revenue CAGR of -13.8%.
Wall Street consensus is Hold based on 4 analysts, beating EPS expectations in 42% of recent quarters with a -4-quarter streak. The consensus price target represents a N/A change from current levels.
Investment risks for Marine Products Corporation include: -29.5% 1-year max drawdown, stretched payout ratio. Volatility risk is characterized by a beta of 1.04x.
No. These computations are purely quantitative model outputs for informational purposes. They do not account for qualitative management shifts or macro events. Always consult a licensed RIA before buying or selling shares.
Disclaimer: This page is for informational purposes only and does not constitute financial advice. All valuation models, scores, and target estimates are automated computations under stated assumptions and should not be relied upon as the sole basis for any investment decision.